Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
about
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementCul4A is required for hematopoietic stem-cell engraftment and self-renewalCul4A is required for hematopoietic cell viability and its deficiency leads to apoptosisPulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.Role of proteasomes in disease.Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Discovery of novel proteasome inhibitors using a high-content cell-based screening system5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization.Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathwayIn vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.Dihydroxypentamethoxyflavone down-regulates constitutive and inducible signal transducers and activators of transcription-3 through the induction of tyrosine phosphatase SHP-1Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway.NF-kappa B as a therapeutic target in autoimmune disease.Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.Treatment of myeloma: cure vs controlPiperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1.Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.Acrocyanosis and necrotic purpura: a manifestation of multiple myeloma and Type I cryoglobulinemia.Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells.Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma.
P2860
Q27011865-BF0C4683-6DD8-4858-90CB-185093DFB0FAQ28587021-0C6B569D-62F4-4712-A566-5A49D70B2E8DQ28593134-10CC4419-EC1A-4B98-B228-539639CB77E3Q30487871-226FFDCF-E76E-4A78-A902-838613460DDAQ33307877-F68E1F86-BD17-4F38-BD9C-55229B85246CQ33409172-7C1F9C16-21E0-470A-9E51-C8233F821B0FQ33521189-9E78E17B-0D03-401E-BEA9-D07CACD9D482Q33598740-56802849-C24F-475C-B00F-401B2BC37169Q33879341-2411AD32-0C32-4E1F-9EAE-64C04AC09ACDQ34236653-FFBCB3C3-4FCA-4F16-A18F-B5F092D08936Q34342251-83B66489-DAF4-4B35-B23C-2A4CF793B7BAQ34501627-E7A42EDC-2644-453C-A328-D13AFB777108Q34606889-42699360-790C-4599-ADA6-F25852EB4155Q35415906-DD30CDA3-EF8C-4A3C-8CD4-F1990D97AD41Q35571044-6376C010-EE19-4439-AF2A-2D34306B2C0AQ36540685-D1E5666B-9089-4865-8D65-97999AD7D689Q36621295-68B1B14C-73A7-4B39-95E4-B1D68906AA56Q36709522-3BDE9BCA-16BB-4BEE-B2FF-D14B46F8950DQ37109225-7F63B9C3-AB0F-4ADB-AD60-B6FDA32B77A8Q37273485-3CBE387C-CD38-4F37-BA3C-13F0E5B8CBE1Q37274132-B901E464-9186-4B90-B26E-7A148F230577Q37284081-06711EDE-617D-4595-B475-1A6EED8836D9Q37687419-5CC9F6AC-3040-4854-BFE7-D44DCFE4028BQ38364018-8D42BE02-18D5-4B87-BB69-6ABF470FFE34Q38805723-E8469784-57A1-482F-8EF2-06C2F46757F6Q38847744-154D9AD0-C4B2-4CE3-A129-5C6AEA05A5BDQ39587408-4F91D6C6-7B3D-4E53-BE59-3554AA296FC0Q39902329-05F65549-9261-4330-8479-8E4A45A41D9FQ40134051-DF03416E-1F20-4635-B101-B64D6CE16952Q40134056-A2CDD6DC-229F-42DD-8BB8-0F797B07AAE6Q41882913-E8494968-3F45-4A05-8B12-1FFEC1AB33F4Q42087798-A59C5F1C-6BA5-448B-B827-74E37DB345DBQ42911212-78A9C6BC-283A-4E89-9E31-D626F624A5F2Q42932963-7DBA12CE-4D09-482D-A0FA-00E130958AECQ43461703-6C7C355F-C93B-4508-88FD-695127F8A98DQ53975226-3EEADB9C-9AF7-4601-9DF7-18A7FA5A0670Q55281764-CE89D9FA-1B73-42BF-89C3-8E8F1BEA9BD5
P2860
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
@ast
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
@en
type
label
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
@ast
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
@en
prefLabel
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
@ast
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
@en
P2860
P356
P1433
P1476
Proteasome inhibitor bortezomib for the treatment of multiple myeloma
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404278
P50
P577
2006-06-29T00:00:00Z